References
- British Thoracic Society. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52(suppl 5)S1–S28
- Rennard S, Decramer M, Calverley P MA, Pride N B, Soriano J B, Vermiere P A, Vestbo J. Impact of COPD in North America and Europe in 2000: subjects' perspective of confronting COPD international survey. Eur Respir J 2002; 20: 799–805, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Douglas S L, Daly B J, Gordon N, Brennan P F. Survival and quality of life: short‐term versus long‐term ventilator patients. Crit Care Med Dec, 2002; 30(12)2655–2662, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- National Institutes of Health. National Heart, Lung and Blood Institute. Morbidity and Mortality: 2002 Chart Book on Cardiovascular, Lung and Blood Diseases. May, 2002, http://www.nhlbi.nih.gov.
- Connors A F, Dawson N V, Thomas C, Harrell F E, Jr, Desbiens N, Fulkerson W J, Kussin P, Bellamy P, Goldman L, Knaus W A. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996; 154: 959–967, [PUBMED], [INFOTRIEVE], [CSA]
- Osman L M, Godden D J, Friend J AR, Legge J S, Douglas J G. Quality of life and hospital re‐admission in patients with chronic obstructive pulmonary disease. Thorax 1997; 52: 67–71, [PUBMED], [INFOTRIEVE]
- Emerman C L, Efrron D, Lukens T W. Spirometric criteria for hospital admission of patients with acute exacerbation of COPD. Chest 1991; 99: 595–599, [PUBMED], [INFOTRIEVE]
- Almagro P, Calbo E, Ochoa de Echaguen A, Barreiro B, Quintana S, Heredia J L, Garau J. Mortality after hospitalization for COPD. Chest 2002; 121: 1441–1448, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Seneff M G, Wagner D F, Wagner R P, Zimmerman J E, Knaus W A. Hospital and 1‐year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995; 274: 1852–1857, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Groenewegen K H, Schols A M.W.J, Wouters E F.M. Mortality and mortality‐related factors after hospitalization for acute exacerbation of COPD. Chest 2003; 124: 459–467, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Fuso L, Incalzi R A, Pistelli R, Muzzolon R, Valente S, Pagliari G, Gliozzi F, Ciappi G. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995; 98: 272–277, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Seemungal T AR, Donaldson G C, Bhowmik A, Jeffries D J, Wedzicha J A. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1608–1613, [PUBMED], [INFOTRIEVE], [CSA]
- Seemungal T A, Donaldson G C, Paul E A, Bestall J C, Jeffries D J, Wedzicha J A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418–1422, [PUBMED], [INFOTRIEVE], [CSA]
- Wouter E FM. Economic analysis of the confronting COPD survey: overview of results. Respir Med 2003; 97(suppl C)S3–S14, [CROSSREF]
- Sullivan S D, Ramsey S D, Lee T A. The economic burden of COPD. Chest 2000; 117: 5S–9S, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hilleman D E, Dewan N, Malesker M, Friedman M. Pharmacoeconomics evaluation of COPD. Chest 2000; 118: 1278–1285, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ward M M, Javitz H S, Smith W M, Bakst A. Direct medical cost of chronic obstructive pulmonary disease in the USA. Respir Med 2001; 117: 1123–1129
- Rutten van‐Molken M PMH, Feenstra T L. The burden of asthma and chronic obstructive pulmonary disease. PharmacoEconomics 2001; 19(suppl 2)1–6
- Andersson F, Borg S, Jansson S A, Jonsson A C, Ericson A, Prutz C, Ronmark E, Lundback B. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002; 96(9)700–708, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Grasso M E, Weller W E, Shaffer T J, Diette G B, Anderson G F. Capitation, managed care and chronic obstructive pulmonary disease. Am J Crit Care Med 1998; 158: 133–138, [CSA]
- Ruchlin H S, Dasbach E J. An economic overview of chronic obstructive pulmonary disease. PharmacoEconomics 2001; 19: 623–642, [PUBMED], [INFOTRIEVE], [CSA]
- Croxton T, Weinemann G, Senior R M, Wise R A, Crapo J D, Buist A S. NHLBI workshop summary clinical research in chronic obstructive pulmonary disease—needs and opportunities. Am J Respir Crit Care Med 2003; 167: 1142–1149, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mahler D A, Wire P, Horstman D, Chang C N, Yates J, Fischer T, Shah T. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166(8)1084–1091, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jones P W, Willits L R, Burge P S, Calverley P M. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003; 21: 68–73, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C, TRial of Inhaled STeroids ANd long‐acting Beta 2 agonist Study Group. Combined salmeterol and fluticasone ineffectiveness the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449–456, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Pederson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74–81, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Alsaeedi A, Sin D D, MaAlister F A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo controlled trials. Am J Med 2002; 113: 59–65, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 158–164, [PUBMED], [INFOTRIEVE], [CSA]
- Collet J P, Shapiro P, Ernst P, Renzi T, Ducruet T, Robinson A, The PARI‐IS Study Steering Committee and Research Group. Effects of an immunostimulant agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156: 1719–1724, [PUBMED], [INFOTRIEVE], [CSA]
- Miravitlles M, Guerrero T, Mayordomo C, Sanchez‐Agudo L, Nicolau F, Segu J L. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO study group. Respiration 2000; 67(5)495–501, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Garcia‐Aymerich J, Barreiro E, Farrero E, Marrades R M, Morera J, Anto J M. Patients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study). Eur Respir J 2000; 16: 1037–1042, [CROSSREF]
- Garcia‐Aymerich J, Monsó E, Marrades R M, Escarrabill J, Félez M A, Sunyer J, Antó J M, and the EFRAM investigators. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation EFRAM study. Am J Respir Crit Care Med September, 2001; 164(Number 6)1002–1007, [CSA]
- Garcia‐Aymerich J, Farrero E, Félez M A, Izquierdo J, Marrades R M, Antó J M, and the EFRAM investigators. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 2003; 58: 100–105, [CROSSREF]
- Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Exec Summ March, 2001, NHLBI/WHO Workshop Report 2001. NIH Publication No. 2701A
- Rodriquez‐Roisin R. Towards a consensus definition for COPD exacerbations. Chest 2000; 117: 398S–401S, [CROSSREF]
- Anthonisen N R, Manfreda J, Warren C P, Hersfield E S, Harding G K, Nelson N A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204, [PUBMED], [INFOTRIEVE]
- American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77–S121, [CSA]
- World Health Organization. Acute Effects on Health of Smog Episodes. World Health Organization, Copenhagen 1992
- Anderson H R, Spix C, Medina S, Schouten J P, Castellsague J, Rossi G, Zmirou D, Touloumi G, Wojtyniak B, Ponka A, Bacharova L, Schwrtz J, Katsouyanni K. Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project. Eur Respir J 1997; 10: 1064–1071, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Donaldson G C, Seemungal T A, Jeffries D J, Wedzicha J A. Effect of environmental temperature on symptoms, lung function and mortality in COPD patients. Eur Respir J 1999; 13: 844–849, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Jarad N A, Wedzicha J A, Burge P S, Calverley P M. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE study group. Respir Med 1999; 93: 161–166, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Burge S, Wedzicha J A. COPD exacerbations: definitions and classifications. Eur Respir J 2003; 21(suppl 41)46s–53s, [CROSSREF]
- Woolhouse I S, Hill S L, Stockley R A. Symptoms resolution assessed using a patient directed diary card during treatment of acute excacerbations of chronic bronchitis. Thorax 2001; 56: 947–953, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Burge P S, Calverley P M, Jones P W, Spencer S, Anderson J A, Maslen T K. Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297–1303, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Vestbo J, Sorenson T, Lange P, Brix A, Torre P, Viskum K. Long‐term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: randomized control trial. Lancet 1999; 353: 1819–1823, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Pauwels R A, Lofdahl C G, Laitinen L A, Schouten J P, Postma D S, Pride N B, Ohlsson S V. Long‐term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European respiratory society study on chronic obstructive pulmonary disease. N Engl J Med 1999; 340: 1948–1953, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen city heart study group. Am J Respir Crit Care Med 1996; 153: 1530–1535, [PUBMED], [INFOTRIEVE], [CSA]
- Decramer M, Gosselink R, Troosters T, Verschueren M, Evers G. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J 1997; 10: 417–423, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Pouw E M, Ten Velde G P, Croonen B H, Kester A D, Schols A M. Early non‐elective readmission for chronic obstructive pulmonary disease is associated with weight loss. Clin Nutr Apr, 2000; 19(2)95–99, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fan V S, Curtis J R, Tu S P, McDonell M B, Fihn S D. Using quality of life to predict hospitalization and mortality in patients with obstructive lung diseases. Chest 2002; 122: 429–436, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Niewoehner D E, Collins D, Erbland M L. Relation of FEV (1) to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Department of veterans affairs cooperative study group. Am J Respir Crit Care Med Apr, 2000; 161(4 Pt 1)1201–1205, [PUBMED], [INFOTRIEVE], [CSA]
- Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 1995; 8: 1333–1338, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Vestbo J, Prescott E, Lange P, Schnohr P, Jensen G. Vital prognosis after hospitalization for COPD: a study of a random population sample. Respir Med May, 1998; 92(5)772–776, [PUBMED], [INFOTRIEVE], [CSA]
- Smith D M, Giobbie‐Hurder A, Weinberger M, Oddzone E Z, Henderson W G, Asch D A, Ashton C M, Feussner J R, Ginier P, Huey J M, Hynes D M, Loo L, Mengel C E. Predicting non‐elective hospital readmissions: a multi‐site study. J Clin Epidemiol 2000; 53: 1113–1118, [PUBMED], [INFOTRIEVE], [CSA]
- Nichol K L, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med 1999; 130: 379–403
- Poole P J, Bagg B, Brodie S M, Black P N. Characteristics of patients admitted to hospital with chronic obstructive pulmonary disease. NZ Med J 1997; 110: 272–275
- Buchi S, Villiger B, Sensky T, Schwars F, Wolf C, Buddeberg C. Psychosocial predictors of long‐term success of in‐patient pulmonary rehabilitation of patients with COPD. Eur Respir J 1997; 10: 1272–1277, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Siafakas N M, Vermeire P, Pride N B, Paoletti P, Gibson J, Howard P, Yernault J C, Decramer M, Higenbottam T, Postma D S, Rees J. Optimal assessment and management of chronic obstructive pulmonary disease. Eur Respir J 1995; 8: 1398–1420, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Morrison D, Skwarski K, macNee W. Review of the prescription of domiciliary long‐term oxygen therapy in Scotland. Thorax 1995; 50: 1103–1105, [PUBMED], [INFOTRIEVE]
- Pepin J L, Barjhoux C E, Deschauz C, Brambilla C. ANTADIR. Long Term oxygen therapy at home. Compliance with medical prescription and effective use of therapy. Chest 1996; 109: 1144–1150, [PUBMED], [INFOTRIEVE]
- Coultas D B. Passive smoking and risk of adult asthma and COPD: an update. Thorax 1998; 53: 381–387, [PUBMED], [INFOTRIEVE]
- Roberts C M, Lowe D, Bucknall C E, Ryland I, keely Y, pearson M G, on behalf of the British Thoracic Society Audit Subcommittee of the Standards of Care Committee and the Royal College of Physicians. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax 2002; 57: 137–141, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kanner R E, Anthonisen N R, Connett J E, The Lung Health Study Research Group. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex‐smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 358–364, [PUBMED], [INFOTRIEVE], [CSA]
- Salas M, Hofman A, Striker B H. Confounding by indication: an example or a variation in the use of epidemiologic terminology. Am J Epidemiol 1999; 149: 981–983, [PUBMED], [INFOTRIEVE], [CSA]
- Stockley R A, O'Brien C, Pye A, Hill S L. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638–1645, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Soler N, Torres A, Ewig S, Gonzales J, Cellis R, El‐Ebiary M, Hernandez C, Rodriguez‐Roisin R. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157: 1498–1505, [PUBMED], [INFOTRIEVE], [CSA]
- Macfarlane J T, Colville A, Guion A, Marfarlane R M, Rose D H. Prospective study of aetiology and outcome of adult lower‐respiratory‐tract infections in the community. Lancet 1993; 341: 511–514, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wilson R. The role of infection in COPD. Chest 1998; 113: 242S–248S, Controversial[PUBMED], [INFOTRIEVE]
- Sethi S, Evans N, Grant B JB, Murphy T F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347(7)465–471, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Seemungal T, Harper‐Owen R, Bhowmik A, Moric I, Sanderson G, Message S, MacCallum P, Meade T W, Jeffries D J, Johnston S L, Wedzicha J A. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 1618–1623, [PUBMED], [INFOTRIEVE], [CSA]
- Sethi S. infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000; 117(suppl 2)380S–385S, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Mogulkoc N, Karakurt S, Isalska B, Bayindir U, Celikel T, Korten V, Colpan N. Acute purulent exacerbation of chronic obstructive pulmonary disease and chlamydia pneumoniae infection. Am J Respir Crit Care Med 1999; 160: 349–353, [PUBMED], [INFOTRIEVE], [CSA]
- Tager I, Speizer F E. Role of infection in chronic bronchitis. N Engl J Med 1975; 292: 563–571, [PUBMED], [INFOTRIEVE]
- Murphy T F, Sethi S. Bacterial infection in chronic bronchitis. Am Rev Respir dis 1992; 146: 1067–1083, [PUBMED], [INFOTRIEVE], [CSA]
- Hirshmann J V. Do bacteria cause exacerbations of COPD?. Chest 2000; 118: 193–203, [CROSSREF]
- Murphy T F, Sethi S, Niedermann M S. The role of bacteria in exacerbations of COPD: a constructive view. Chest 2000; 118: 204–209, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Smith C B, Golden C, Klauber M R, Kanner R, Rensetti A. Interactions between viruses and bacteria in patients with chronic bronchitis. J Infect Dis 1976; 143: 552–561
- Gump D W, Phillips C A, Forsyth B R, McIntosh K, Lamborn K R, Stouch W H. Role of infection in chronic bronchitis. Am Rev Respir Dis 1976; 113: 465–474, [PUBMED], [INFOTRIEVE]
- McHardy V U, Inglis J M, Calder M A, Crofton J W, Gregg I, Ryland D A, Taylor P, Chadwick M, Coombs D, Riddell R W. A study of infective and other factors in exacerbations of chronic bronchitis. Br J Dis Chest 1980; 74: 228–238, [PUBMED], [INFOTRIEVE]
- Fagon J Y, Chastre J. Severe exacerbations of COPD patients: the role of pulmonary infections. Sem Respir Infect 1996; 11: 109–118, [CSA]
- Murphy T F, Sethi S, Klingman K L, Brueggemann A AB, Doem G V. Simultaneous respiratory tract colonization by multiple strains of nontypeable. Haemophilus influenzae in chronic obstructive pulmonary disease: implications for antibiotic therapy. J Infect Dis 1999; 180: 404–409, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Miravitlles M, Espinosa C, Fernandez‐Laso E, Martos J A, Maldonada J A, Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study group of bacterial infection in CODP. Chest 1999; 116: 40–46, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Anthonisen N R. Bacterial and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 526–527, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Fletcher C, Peto R, Tinker C, Speizer F. The natural history of chronic bronchitis and emphysema. Oxford University Press, Oxford 1976
- Howard P. A long‐term follow‐up of respiratory symptoms and ventilatory function in a group of working men. Br J Ind Med 1970; 27: 326–333, [PUBMED], [INFOTRIEVE]
- Bates D. The fate of chronic bronchitis: a report of the 10 year follow‐up in the Canadian Department of Veteran's Affairs coordinated study of chronic bronchitis. Am Rev Respir Dis 1973; 108: 1043–1065, [PUBMED], [INFOTRIEVE]
- Kanner R E, Renzetti A D, Jr., Klauber M R, Smith C B, Golden C A. Variables associated with changes in spirometry in patients with obstructive lung diseases. Am J Med Jul, 1979; 67(1)44–50, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Burrows B. Predictors of loss of lung function and mortality in obstructive lung disease. Eur Respir Rev 1991; 1: 340–345
- Peto R, Speizer F E, Cochran A L. The relation in adults of air‐flow obstruction, but not mucus hypersecretion, to mortality from chronic lung disease. Am Rev Respir Dis 1983; 128: 491–500, [PUBMED], [INFOTRIEVE]
- Ferrer M, Alonso J, Morera J, Marrades R M, Khalaf A, Aguar M C, Plaza V, Prieto L, Anto J M. Chronic obstructive pulmonary disease stage and health‐related quality of life: the quality of life of chronic obstructive pulmonary disease study group. Ann Intern Med 1997; 127: 1072–1079, [PUBMED], [INFOTRIEVE], [CSA]
- Van Ede L, Yzermans C J, Brouwer H J. Clinical and personality profiles and survival in patients with COPD. Chest 1997; 111: 95–98
- Ashutosh K, Haldipur C, Boucher M L. Clinical and personality profiles and survival in patients with COPD. Chest 1997; 111: 95–98, [PUBMED], [INFOTRIEVE]
- Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 1: 1645–1648, [PUBMED], [INFOTRIEVE]
- Traver G A, Cline M G, Burrows B. Predictors of mortality in chronic obstructive pulmonary disease: a 15‐year follow‐up study. Am Rev Respir Dis 1979; 119: 895–902, [PUBMED], [INFOTRIEVE]
- Kanner R, Renzetti A D, Stanesh W M, Barkman H W, Jr, Klauber M R. Predictors of survival in subjects with chronic airflow limitation. Am J Med 1983; 74: 249–255, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Postma D S, Gimeno F, van der Weel L T, Sluiter H J. Assessment of ventilatory variables in survival prediction of patients with chronic airflow obstruction: the importance of reversibility. Eur Respir J Dis 1985; 67: 360–368
- Anthonisen N R, Wright E C, Hodgkin J E. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133: 14–20, [PUBMED], [INFOTRIEVE]
- Burrows B, Earle R H. Prediction of survival in patients with chronic airway obstruction. Am Rev Respir Dis 1969; 99: 865–871, [PUBMED], [INFOTRIEVE]
- Gray D, Gibbons L, Shapiro S H, Martin J G. Nutritional status and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 961–966, [CSA]
- Landbo C, Prescott E, Lange P, Vestbo J, Almdal T P. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1856–1861, [PUBMED], [INFOTRIEVE], [CSA]
- Ferreira I M, Brooks D, Lacasse Y. Nutritional support for individuals with COPD—a meta‐analysis. Chest 2000; 117: 672–678, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Incalzi R A, Fuso L, DeRosa M, Forastiere F, Rapiti E, Nardecchia B, Pistelli R. Co‐morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997; 10: 2794–2800, [CROSSREF]
- Bowen J B, Votto J J, Thrall R S, Haggerty M C, Stockdale‐Woolley R, Bandyopadhyay T, Zuwallack R L. Functional status and survival following pulmonary rehabilitation. Chest 2000; 118: 697–703, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Benbassat J, Taragin M. Hospital readmissions as a measure of quality of health care. Advantages and limitations. Arch Intern Med 2000; 160: 1074–1081, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Travers G A. Measures of symptoms and life quality to predict emergent use of institutional health care resources in chronic obstructive pulmonary disease. Heart Lung 1988; 17: 689–697
- Anthonisen N R, Connett J E, Kiley J P, Altose M D, Bailey W C, Buist A S, Conway W A, Jr, Enright P L, Kanner R E, O'Hara P. Effects of smoking intervention and the use of inhaled anticholinergic bronchodilator on the rate pf decline of FEV1. The lung health study. JAMA 1994; 272: 1497–1505, [PUBMED], [INFOTRIEVE]
- Vincken W, van Noord J A, Greefhorst A PM, Bantje Th A, Kesten S, Korducki L, Cornelissen P JG. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J 2002; 19: 209–216, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Weinberger M, Oddone E. Strategies to reduce hospital readmissions: a review. QRB 1989; 15: 255–260
- Weinberger M, Oddone E Z, Henderson W G. Does increased access to primary care reduce hospital readmissions. N Engl J Med 1996; 334: 1441–1447, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Celli B R. Current thoughts regarding treatment of chronic obstructive pulmonary disease. Med Clin North Am 1996; 80: 589–609, [PUBMED], [INFOTRIEVE], [CSA]
- Cotton M M, Bucknell C E, Dagg K D, Johnston M K, MacGregor G, Stewart C, Stevenson R D. Early discharge for patients with exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Thorax 2000; 55: 902–906, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hughes S l, Weaver F M, Globbie‐Hurder A, Manheim L, Henderson W, Kubal J D, Ulasevich A, Cummings J, Department of Veterans Affairs Cooperative Study Group on Home‐based Primary Care. Effectiveness of team‐managed home‐based primary care: a randomized multicentre trial. JAMA 2000; 284: 2877–2885, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hermiz O, Comino E, Marks G, Daffurn K, Wilson S, Harris M. Randomized controlled trial of home based care of patients with chronic obstructive pulmonary disease. BMJ 2002; 325: 938, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Griffiths T L, Burr M L, Campbell I A, Lewis‐Jenkins V, Mullins J, Shiels K, Turner‐Lawlor P J, Payne N, Newcombe R G, Ionescu A A, Thomas J, Tunbridge J, Lonescu A A. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomized controlled trial. Lancet 2000; 355: 362–368, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Sin D D, Tu J V. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 580–584, [PUBMED], [INFOTRIEVE], [CSA]
- Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease. Immortal time bias in observational studies. Am J Respir Crit Care Med 2003; 168: 49–53, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bourbeau J, Ernst P, Cockcroft D, Suissa S. Inhaled corticosteroid and hospitalization due to exacerbation of COPD. Eur Respir J 2003; 22: 286–289, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Fan V S, Bryson C L, Randall Curtis J, Stephan D, Pierre‐Olivier Bridevaux M B, McDonell D H. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time–dependent analysis. Am J Respir Crit Care Med 2003; 168(12)1488–1494, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sin D D, McAlister F A, Man S F, Anthonisen N R. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA Nov 5, 2003; 290(17)2301–2312, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Mushlin A I, Black E R, Connolly C A, Buonaccorso K M, Eberly S W. The necessary length of hospital stay for chronic pulmonary disease. JAMA 1991; 266(1)80–83, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hernandez C, Casas A, Escarrabill J, Alonso J, Puig‐Junoy J, Farrero E, Vilagut G, Collvinent B, Rodriguez‐Roisin R, Roca J. Home hospitalization of exacerbated chronic obstructive pulmonary disease patients. Eur Respir J 2003; 21: 58–67, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Davies L, Wilkinson M, bonner S, Calverley P M, Angus R M. “Hospital at home” versus hospital care in patients with exacerbations of chronic obstructive pulmonary disease: prospective randomized controlled trial. BMJ 2000; 21: 1265–1268, [CROSSREF]
- Ojoo J C, Moon T, McGlone S, Martin K, Gardiner E D, Greenstone M A, Morice A H. Patients' and carers' preferences in two models of care for acute exacerbation of COPD: results of a randomized controlled trial. Thorax 2002; 57: 167–169, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Skwarska E, Cohen G, Skwarski K M, Lamb C, Bushell D, Parker S, MacNee W. randomized controlled trial of supported discharge in patients with exacerbations of chronic obstructive pulmonary disease. Thorax 2000; 55: 907–912, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ashton C M, Del Junco D J, Souchek J, Wary N P, Mansyur C L. The association of the quality of inpatient care and early readmissions. A metanalysis of the evidence. Med Care 1997; 35: 1044–1059, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Bourbeau J, Julien M, Maltais F, Rouleau M, Beaupre A, Begin R, Renzi P, Nault D, Borycki E, Schwartzman K, Singh R, Collet J P, for the Chronic Obstructive Pulmonary Disease axis of the Respiratory Network Fonds de la Recherche en Sante du Quebec